Development and characterization of an enterovirus 71 (EV71) virus-like particles (VLPs) vaccine produced in Pichia pastoris

References

• Chong P, Hsieh SY, Liu CC, Chou AH, Chang JY, Wu SC, Liu SJ, Chow YH, Su IJ, Klein M. Production of EV71 vaccine candidates. Hum Vaccin Immunother. 2012;8(12):1775–83. doi:10.4161/hv.21739.
   PubMed Web of Science ®Google Scholar
• Huang J, Liao QH, Ooi MH, Cowling BJ, Chang ZR, Wu P, Liu FF, Li Y, Luo L, Yu SB, et al. Epidemiology of recurrent hand, foot and mouth disease, China, 2008–2015. Emerg Infect Dis. 2018;24(3):432–42. doi:10.3201/eid2403.171303.
   PubMed Web of Science ®Google Scholar
• Koh WM, Bogich T, Siegel K, Jin J, Chong EY, Tan CY, Chen MIC, Horby P, Cook AR. The epidemiology of hand, foot and mouth disease in Asia a systematic review and analysis. Pediatr Infect Dis J. 2016;35(10):E285–E300. doi:10.1097/inf.0000000000001242.
   PubMed Web of Science ®Google Scholar
• Chang PC, Chen SC, Chen KT. The current status of the disease caused by enterovirus 71 infections: epidemiology, pathogenesis, molecular epidemiology, and vaccine development. Int J Environ Res Public Health. 2016;13(9):890. doi:10.3390/ijerph13090890.
   PubMed Web of Science ®Google Scholar
• Jang S, Suh SI, Ha SM, Byeon JH, Eun BL, Lee YH, Seo HS, Eun SH, Seol HY. Enterovirus 71-related encephalomyelitis: usual and unusual magnetic resonance imaging findings. Neuroradiology. 2012;54(3):239–45. doi:10.1007/s00234-011-0921-8.
   PubMed Web of Science ®Google Scholar
• Weng KF, Chen LL, Huang PN, Shih SR. Neural pathogenesis of enterovirus 71 infection. Microbes and infection/Institut Pasteur. 2010;12(7):505–10. doi:10.1016/j.micinf.2010.03.006.
   PubMed Web of Science ®Google Scholar
• Gan Z-K, Jin H, Li J-X, Yao X-J, Zhou Y, Zhang X-F, Zhu F-C. Disease burden of enterovirus 71 in rural central China: a community-based survey. Hum Vaccin Immunother. 2015;11(10):2400–05. doi:10.1080/21645515.2015.1059980.
   PubMed Web of Science ®Google Scholar
• Hu Y, Zeng G, Chu K, Zhang J, Han W, Zhang Y, Li J, Zhu F. Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: a further observation. Hum Vaccin Immunother. 2018;14(6):1517–23. doi:10.1080/21645515.2018.1442997.
   PubMed Web of Science ®Google Scholar
• Wei M, Meng F, Wang S, Li J, Zhang Y, Mao Q, Hu Y, Liu P, Shi N, Tao H, et al. 2-year efficacy, immunogenicity, and safety of vigoo enterovirus 71 vaccine in healthy Chinese children: a randomized open-label study. J Infect Dis. 2017;215(1):56–63. doi:10.1093/infdis/jiw502.
   PubMed Web of Science ®Google Scholar
• Zhang W, Kong Y, Jiang Z, Li C, Wang L, Xia J. Comprehensive safety assessment of a human inactivated diploid enterovirus 71 vaccine based on a phase III clinical trial. Hum Vaccin Immunother. 2016;12(4):922–30. doi:10.1080/21645515.2015.1115934.
   PubMed Web of Science ®Google Scholar
• Burrell CJ, Howard CR, Murphy FA, editors. Chapter 11 - vaccines and vaccination. In: Burrell CJ, Howard CR, Murphy FA, editors. Fenner and White’s medical virology. 5th ed. London (UK): Academic Press; 2017. p. 155–67. doi:10.1016/B978-0-12-375156-0.00011-4
   Google Scholar
• Kushnir N, Streatfield SJ, Yusibov V. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine. 2012;31(1):58–83. doi:10.1016/j.vaccine.2012.10.083.
   PubMed Web of Science ®Google Scholar
• Ahmad M, Hirz M, Pichler H, Schwab H. Protein expression in Pichia pastoris: recent achievements and perspectives for heterologous protein production. Appl Microbiol Biotechnol. 2014;98(12):5301–17. doi:10.1007/s00253-014-5732-5.
   PubMed Web of Science ®Google Scholar
• Zhang W, Dai WL, Zhang C, Zhou Y, Xiong P, Wang SX, Ye XH, Liu QW, Zhou DM, Huang Z. A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity. Emerg Microbes Infect. 2018;7:94. doi:10.1038/s41426-018-0094-1.
   PubMed Web of Science ®Google Scholar
• Salmons B, Lim PY, Djurup R, Cardosa J. Non-clinical safety assessment of repeated intramuscular administration of an EV-A71 VLP vaccine in rabbits. Vaccine. 2018;36(45):6623–30. doi:10.1016/j.vaccine.2018.09.062.
   PubMed Web of Science ®Google Scholar
• Sun SY, Gao F, Mao QY, Shao J, Jiang LP, Liu DW, Wang YP, Yao X, Wu X, Sun B, et al. Immunogenicity and protective efficacy of an EV71 virus-like particle vaccine against lethal challenge in newborn mice. Hum Vaccin Immunother. 2015;11(10):2406–13. doi:10.1080/21645515.2015.1053675.
   PubMed Web of Science ®Google Scholar
• Chung YC, Huang JH, Lai CW, Sheng HC, Shih SR, Ho MS, Hu YC. Expression, purification and characterization of enterovirus-71 virus-like particles. World J Gastroenterol. 2006;12(6):921–27. doi:10.3748/wjg.v12.i6.921.
   PubMed Web of Science ®Google Scholar
• Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, Chou ST, Hu YC. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal, challenge. Vaccine. 2008;26(15):1855–62. doi:10.1016/j.vaccine.2008.01.058.
   PubMed Web of Science ®Google Scholar
• Ku ZQ, Liu QW, Ye XH, Cai YC, Wang XL, Shi JP, Li DP, Jin X, An WQ, Huang Z. A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice. Vaccine. 2014;32(34):4296–303. doi:10.1016/j.vaccine.2014.06.025.
   PubMed Web of Science ®Google Scholar
• Lim PY, Hickey AC, Jamiluddin MF, Hamid S, Kramer J, Santos R, Bossart KN, Cardosa MJ. Immunogenicity and performance of an enterovirus 71 virus-like-particle vaccine in nonhuman primates. Vaccine. 2015;33(44):6017–24. doi:10.1016/j.vaccine.2015.05.108.
   PubMed Web of Science ®Google Scholar
• Somasundaram B, Chang C, Fan YY, Lim PY, Cardosa J, Lua L. Characterizing Enterovirus 71 and Coxsackievirus A16 virus-like particles production in insect cells. Methods. 2016;95:38–45. doi:10.1016/j.ymeth.2015.09.023.
   PubMed Web of Science ®Google Scholar
• Chung CY, Chen CY, Lin SY, Chung YC, Chiu HY, Chi WK, Lin YL, Chiang BL, Chen WJ, Hu YC. Enterovirus 71 virus-like particle vaccine: improved production conditions for enhanced yield. Vaccine. 2010;28(43):6951–57. doi:10.1016/j.vaccine.2010.08.052.
   PubMed Web of Science ®Google Scholar
• Zhang C, Ku ZQ, Liu QW, Wang XL, Chen T, Ye XH, Li DP, Jin X, Huang Z. High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice. Vaccine. 2015;33(20):2335–41. doi:10.1016/j.vaccine.2015.03.034.
   PubMed Web of Science ®Google Scholar
• Li HY, Han JF, Qin CF, Chen R. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine. 2013;31(32):3281–87. doi:10.1016/j.vaccine.2013.05.019.
   PubMed Web of Science ®Google Scholar
• Mao Q, Li N, Yu X, Yao X, Li F, Lu F, Zhuang H, Liang Z, Wang J. Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71. Arch Virol. 2012;157(1):37–41. doi:10.1007/s00705-011-1136-3.
   PubMed Web of Science ®Google Scholar
• Li X, Mao C, Ma S, Wang X, Sun Z, Yi Y, Guo M, Shen X, Sun L, Bi S. Generation of neutralizing monoclonal antibodies against Enterovirus 71 using synthetic peptides. Biochem Biophys Res Commun. 2009;390(4):1126–28. doi:10.1016/j.bbrc.2009.09.103.
   PubMed Web of Science ®Google Scholar
• Liang Z, Mao Q, Gao Q, Li X, Dong C, Yu X, Yao X, Li F, Yin W, Li Q, et al. Establishing China’s national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines. Vaccine. 2011;29(52):9668–74. doi:10.1016/j.vaccine.2011.10.018.
   PubMed Web of Science ®Google Scholar
• Liu Q, Yan K, Feng Y, Huang X, Ku Z, Cai Y, Liu F, Shi J, Huang Z. A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge. Vaccine. 2012;30(47):6642–48. doi:10.1016/j.vaccine.2012.08.071.
   PubMed Web of Science ®Google Scholar
• Mao QY, Wang YP, Bian LL, Xu M, Liang ZL. EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases. Emerg Microbes Infect. 2016;5(7):e75. doi:10.1038/emi.2016.73.
   PubMedGoogle Scholar
• Liu CC, Guo MS, Lin FH, Hsiao KN, Chang KH, Chou AH, Wang YC, Chen YC, Yang CS, Chong PC. Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system. PLoS One. 2011;6(5):e20005. doi:10.1371/journal.pone.0020005.
   PubMed Web of Science ®Google Scholar
• Lin SY, Chiu HY, Chiang BL, Hu YC. Development of EV71 virus-like particle purification processes. Vaccine. 2015;33(44):5966–73. doi:10.1016/j.vaccine.2015.04.077.
   PubMed Web of Science ®Google Scholar
• Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z, Li X, Yin W, Shen X, Porta C, et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol. 2012;19(4):424–29. doi:10.1038/nsmb.2255.
   PubMed Web of Science ®Google Scholar
• Dong CH, Liu LD, Zhao HL, Wang JJ, Liao Y, Zhang XM, Na RX, Liang Y, Wang LC, Li QH. Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. Vaccine. 2011;29(37):6269–75. doi:10.1016/j.vaccine.2011.06.044.
   PubMed Web of Science ®Google Scholar
• Liu LD, Mo ZJ, Liang ZL, Zhang Y, Li RC, Ong KC, Wong KT, Yang EX, Che YC, Wang JJ, et al. Immunity and clinical efficacy of an inactivated enterovirus 71 vaccine in healthy Chinese children: a report of further observations. BMC Med. 2015;13:226. doi:10.1186/s12916-015-0448-7.
   PubMed Web of Science ®Google Scholar
• Chen YJ, Meng FY, Mao QY, Li JX, Wang H, Liang ZL, Zhang YT, Gao F, Chen QH, Hu YM, et al. Clinical evaluation for batch consistency of an inactivated enterovirus 71 vaccine in a large-scale phase 3 clinical trial. Hum Vaccin Immunother. 2014;10(5):1366–72. doi:10.4161/hv.28397.
   PubMed Web of Science ®Google Scholar
• Ku Z, Ye X, Huang X, Cai Y, Liu Q, Li Y, Su Z, Huang Z. Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps. PLoS One. 2013;8(2):e57601. doi:10.1371/journal.pone.0057601.
   PubMed Web of Science ®Google Scholar
• Bek EJ, Hussain KM, Phuektes P, Kok CC, Gao Q, Cai F, Gao Z, McMinn PC. Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection. Vaccine. 2011;29(29–30):4829–38. doi:10.1016/j.vaccine.2011.04.070.
   PubMed Web of Science ®Google Scholar
• Lin Y-L, Yu C-I, Hu Y-C, Tsai T-J, Kuo Y-C, Chi W-K, Lin A-N, Chiang B-L. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. Vaccine. 2012;30(7):1305–12. doi:10.1016/j.vaccine.2011.12.081.
   PubMed Web of Science ®Google Scholar
• Vecchi S, Bufali S, Skibinski DA, O’Hagan DT, Singh M. Aluminum adjuvant dose guidelines in vaccine formulation for preclinical evaluations. J Pharm Sci. 2012;101(1):17–20. doi:10.1002/jps.22759.
   PubMed Web of Science ®Google Scholar
• Di, Pasquale A, Preiss S, Tavares Da Silva F, Garcon N. Vaccine adjuvants: from 1920 to 2015 and Beyond. Vaccines (Basel). 2015;3(2):320–43. doi:10.3390/vaccines3020320.
   PubMed Web of Science ®Google Scholar
• He P, Zou Y, Hu Z. Advances in aluminum hydroxide-based adjuvant research and its mechanism. Hum Vaccin Immunother. 2015;11(2):477–88. doi:10.1080/21645515.2014.1004026.
   PubMed Web of Science ®Google Scholar
• HogenEsch H, O’Hagan DT, Fox CB. Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want. NPJ Vaccines. 2018;3:51. doi:10.1038/s41541-018-0089-x.
   PubMed Web of Science ®Google Scholar
• Doria-Rose NA, Joyce MG. Strategies to guide the antibody affinity maturation process. Curr Opin Virol. 2015;11:137–47. doi:10.1016/j.coviro.2015.04.002.
   PubMed Web of Science ®Google Scholar
• Liu LD, Zhang Y, Wang JJ, Zhao HL, Jiang L, Che YC, Shi HJ, Li RC, Mo ZJ, Huang T, et al. Study of the integrated immune response induced by an inactivated EV71 vaccine. PLoS One. 2013;8(1):e54451. doi:10.1371/journal.pone.0054451.
   PubMed Web of Science ®Google Scholar